{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:29:04Z","timestamp":1762374544732,"version":"3.28.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"DOI":"10.7759\/cureus.72559","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T16:14:57Z","timestamp":1730132097000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Melatonin as a Promising Intervention for Migraine Prevention: A Systematic Review of Randomized Control Trials"],"prefix":"10.7759","author":[{"given":"Bhavana","family":"Nelakuditi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bindu Jyothi","family":"Dandamudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrina Antheia M","family":"Dimaano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nensi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamah","family":"AlQassab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Al-Sulaitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8434-y","article-title":"An update on migraine: current understanding and future directions","volume":"264","author":"Puledda F","year":"2017","unstructured":"Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017, 264:2031-9. 10.1007\/s00415-017-8434-y","journal-title":"J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3\u2005mg, amitriptyline 25\u2005mg and placebo for migraine prevention","volume":"87","author":"Gon\u00e7alves AL","year":"2016","unstructured":"Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3\u2005mg, amitriptyline 25\u2005mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016, 87:1127-32. 10.1136\/jnnp-2016-313458","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse DC","year":"2010","unstructured":"Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010, 81:428-32. 10.1136\/jnnp.2009.192492","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt AK","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, et al.. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021, 17:501-14. 10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein SD","year":"2015","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015, 21:973-89. 10.1212\/CON.0000000000000199","journal-title":"Continuum (Minneap Minn)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.07.004","article-title":"Preventive treatment for episodic migraine","volume":"37","author":"Parikh SK","year":"2019","unstructured":"Parikh SK, Silberstein SD. Preventive treatment for episodic migraine. Neurol Clin. 2019, 37:753-70. 10.1016\/j.ncl.2019.07.004","journal-title":"Neurol Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton RB","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68:343-9. 10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"key":"ref8","article-title":"Migraine headache prophylaxis","volume":"1","author":"Ha H","year":"2019","unstructured":"Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019, 1:17-24.","journal-title":"Am Fam Physician"},{"key":"ref9","article-title":"Migraine overview and summary of current and emerging treatment options","volume":"25","author":"Peters GL","year":"2019","unstructured":"Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019, 25:S23-34.","journal-title":"Am J Manag Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani J","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021, 61:1021-39. 10.1111\/head.14153","journal-title":"Headache"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00082.x","article-title":"Determinants of patient satisfaction with migraine therapy","volume":"20","author":"Davies GM","year":"2000","unstructured":"Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000, 20:554-60. 10.1046\/j.1468-2982.2000.00082.x","journal-title":"Cephalalgia"},{"key":"ref12","article-title":"Satisfaction of the migraine patient attending neurology clinics: results of CIEN-mig project (II) (Article in Spanish)","volume":"50","author":"Pascual J","year":"2010","unstructured":"Pascual J, S\u00e1nchez del R\u00edo M, Jim\u00e9nez MD, et al.. Satisfaction of the migraine patient attending neurology clinics: results of CIEN-mig project (II) (Article in Spanish). Rev Neurol. 2010, 50:641-5.","journal-title":"Rev Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein SD","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012, 78:1337-45. 10.1212\/WNL.0b013e3182535d20","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03516-9","article-title":"The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study","volume":"24","author":"Farzin K","year":"2024","unstructured":"Farzin K, Kheiltash A, Tafakhori A, Nakhjiri NE, Sabet MS, Nayeri ND. The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study. BMC Neurol. 2024, 24:2. 10.1186\/s12883-023-03516-9","journal-title":"BMC Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.30476\/ijms.2023.97782.2965","article-title":"The effect of melatonin on reducing the frequency and severity of migraine attacks: a double-blind, randomized clinical trial","volume":"49","author":"Mehramiri A","year":"2024","unstructured":"Mehramiri A, Shalilahmadi D, Mohamadianinejad SE, Kouti L, Hosseinpour Y. The effect of melatonin on reducing the frequency and severity of migraine attacks: a double-blind, randomized clinical trial. Iran J Med Sci. 2024, 49:313-21. 10.30476\/ijms.2023.97782.2965","journal-title":"Iran J Med Sci"},{"key":"ref17","article-title":"A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children","volume":"12","author":"FA R","year":"2018","unstructured":"FA R, FA F, SE L. A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children. Iran J Child Neurol. 2018, 12:47-54.","journal-title":"Iran J Child Neurol"},{"key":"ref18","article-title":"Study protocol for assessing the effectiveness of agomelatine on the severity and frequency of episodic migraine attacks without aura: a randomized triple-blind, placebo-controlled trial","volume":"25","author":"Nayeri ND","year":"2024","unstructured":"Nayeri ND, Farzin K, Sabet MS, Tafakhori A. Study protocol for assessing the effectiveness of agomelatine on the severity and frequency of episodic migraine attacks without aura: a randomized triple-blind, placebo-controlled trial. Shiraz E-Med J. 2024, 25:e142956.","journal-title":"Shiraz E-Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f9618c","article-title":"Prophylaxis of migraine with melatonin: a randomized controlled trial","volume":"75","author":"Alstadhaug KB","year":"2010","unstructured":"Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010, 75:1527-32. 10.1212\/WNL.0b013e3181f9618c","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0285","article-title":"Home-based trials in adolescent migraine: a randomized clinical trial","volume":"74","author":"Gelfand AA","year":"2017","unstructured":"Gelfand AA, Qubty W, Patniyot I, Grimes B, Pletcher MJ, Goadsby PJ, Cummings SR. Home-based trials in adolescent migraine: a randomized clinical trial. JAMA Neurol. 2017, 74:744-5. 10.1001\/jamaneurol.2017.0285","journal-title":"JAMA Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.31069\/japsr.v5i2.03","article-title":"Melatonin role in the prophylaxis of migraine","volume":"5","author":"Sati V","year":"2022","unstructured":"Sati V, Jauhari R, Rao N, Godiyal P, Babbar A. Melatonin role in the prophylaxis of migraine. J Appl Pharma Sci Res. 2022, 5:17-27. 10.31069\/japsr.v5i2.03","journal-title":"J Appl Pharma Sci Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-013-0258-1","article-title":"Sleep-related headache and its management","volume":"15","author":"Singh NN","year":"2013","unstructured":"Singh NN, Sahota P. Sleep-related headache and its management. Curr Treat Options Neurol. 2013, 15:704-22. 10.1007\/s11940-013-0258-1","journal-title":"Curr Treat Options Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05159.x","article-title":"Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs","volume":"45","author":"Kelman L","year":"2005","unstructured":"Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005, 45:904-10. 10.1111\/j.1526-4610.2005.05159.x","journal-title":"Headache"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2011.00895.x","article-title":"Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies","volume":"51","author":"Wilhelmsen M","year":"2011","unstructured":"Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, G\u00f6genur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011, 51:270-7. 10.1111\/j.1600-079X.2011.00895.x","journal-title":"J Pineal Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-017-0803-x","article-title":"The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine","volume":"117","author":"Ansari M","year":"2017","unstructured":"Ansari M, Karkhaneh A, Kheirollahi A, Emamgholipour S, Rafiee MH. The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine. Acta Neurol Belg. 2017, 117:677-85. 10.1007\/s13760-017-0803-x","journal-title":"Acta Neurol Belg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2174\/1574886309666140605114614","article-title":"Safety and efficacy of melatonin in pediatric migraine prophylaxis","volume":"10","author":"Fallah R","year":"2015","unstructured":"Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015, 10:132-5. 10.2174\/1574886309666140605114614","journal-title":"Curr Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.02.067","article-title":"Melatonin enhances antinociceptive effects of delta-, but not mu-opioid agonist in mice","volume":"1043","author":"Li SR","year":"2005","unstructured":"Li SR, Wang T, Wang R, Dai X, Chen Q, Li RD. Melatonin enhances antinociceptive effects of delta-, but not mu-opioid agonist in mice. Brain Res. 2005, 1043:132-8. 10.1016\/j.brainres.2005.02.067","journal-title":"Brain Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.002","article-title":"Melatonin reduces night blood pressure in patients with nocturnal hypertension","volume":"119","author":"Grossman E","year":"2006","unstructured":"Grossman E, Laudon M, Yalcin R, et al.. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006, 119:898-902. 10.1016\/j.amjmed.2006.02.002","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v2.i6.82","article-title":"Role of melatonin on diabetes-related metabolic disorders","volume":"2","author":"Espino J","year":"2011","unstructured":"Espino J, Pariente JA, Rodr\u00edguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes. 2011, 2:82-91. 10.4239\/wjd.v2.i6.82","journal-title":"World J Diabetes"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079x.1996.tb00260.x","article-title":"Melatonin reduces nitric oxide synthase activity in rat hypothalamus","volume":"20","author":"Bettahi I","year":"1996","unstructured":"Bettahi I, Pozo D, Osuna C, Reiter RJ, Acu\u00f1a-Castroviejo D, Guerrero JM. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res. 1996, 20:205-10. 10.1111\/j.1600-079x.1996.tb00260.x","journal-title":"J Pineal Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-016-0049-y","article-title":"Melatonin in chronic pain syndromes","volume":"5","author":"Danilov A","year":"2016","unstructured":"Danilov A, Kurganova J. Melatonin in chronic pain syndromes. Pain Ther. 2016, 5:1-17. 10.1007\/s40122-016-0049-y","journal-title":"Pain Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015187601628","article-title":"Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting","volume":"21","author":"Zisapel N","year":"2001","unstructured":"Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. 2001, 21:605-16. 10.1023\/a:1015187601628","journal-title":"Cell Mol Neurobiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124742","article-title":"MT1 and MT2 melatonin receptors: a therapeutic perspective","volume":"56","author":"Liu J","year":"2016","unstructured":"Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016, 56:361-83. 10.1146\/annurev-pharmtox-010814-124742","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-021-00447-6","article-title":"Agomelatine exerts an anti-inflammatory effect by inhibiting microglial activation through TLR4\/NLRP3 pathway in pMCAO rats","volume":"40","author":"Chumboatong W","year":"2022","unstructured":"Chumboatong W, Khamchai S, Tocharus C, Govitrapong P, Tocharus J. Agomelatine exerts an anti-inflammatory effect by inhibiting microglial activation through TLR4\/NLRP3 pathway in pMCAO rats. Neurotox Res. 2022, 40:259-66. 10.1007\/s12640-021-00447-6","journal-title":"Neurotox Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/nu14163335","article-title":"The pathogenetic role of melatonin in migraine and its theoretic implications for pharmacotherapy: a brief overview of the research","volume":"14","author":"Zdu\u0144ska A","year":"2022","unstructured":"Zdu\u0144ska A, Cegielska J, Domitrz I. The pathogenetic role of melatonin in migraine and its theoretic implications for pharmacotherapy: a brief overview of the research. Nutrients. 2022, 14:3335. 10.3390\/nu14163335","journal-title":"Nutrients"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12749","article-title":"Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome","volume":"43","author":"Ng QX","year":"2018","unstructured":"Ng QX, Soh AY, Lim DY, Yeo WS. Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome. J Clin Pharm Ther. 2018, 43:752-6. 10.1111\/jcpt.12749","journal-title":"J Clin Pharm Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16011111","article-title":"Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression","volume":"16","author":"De Berardis D","year":"2015","unstructured":"De Berardis D, Fornaro M, Serroni N, et al.. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci. 2015, 16:1111-30. 10.3390\/ijms16011111","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315584869","article-title":"Agomelatine and migraine management: a successfully treated case series","volume":"5","author":"Plasencia-Garc\u00eda BO","year":"2015","unstructured":"Plasencia-Garc\u00eda BO, Romero-Guillena SL, Quir\u00f3s-L\u00f3pez A, Ruiz-Doblado S. Agomelatine and migraine management: a successfully treated case series. Ther Adv Psychopharmacol. 2015, 5:243-5. 10.1177\/2045125315584869","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114431","article-title":"A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder","volume":"447","author":"Zhou Q","year":"2023","unstructured":"Zhou Q, Li X, Yang D, Xiong C, Xiong Z. A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder. Behav Brain Res. 2023, 447:114431. 10.1016\/j.bbr.2023.114431","journal-title":"Behav Brain Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s40303-015-0011-7","article-title":"A systematic review of agomelatine-induced liver injury","volume":"3","author":"Freiesleben SD","year":"2015","unstructured":"Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015, 3:4. 10.1186\/s40303-015-0011-7","journal-title":"J Mol Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5374","article-title":"Effect of regulatory interventions on agomelatine use in Spain: a multiple intervention time-series analysis in a nationwide electronic healthcare record database","volume":"31","author":"Gonz\u00e1lez-Bermejo D","year":"2022","unstructured":"Gonz\u00e1lez-Bermejo D, Castillo-Cano B, Rodr\u00edguez-Pascual A, Garc\u00eda-Mart\u00edn MF, \u00c1lvarez-Guti\u00e9rrez A, Montero-Corominas D, Huerta-\u00c1lvarez C. Effect of regulatory interventions on agomelatine use in Spain: a multiple intervention time-series analysis in a nationwide electronic healthcare record database. Pharmacoepidemiol Drug Saf. 2022, 31:294-301. 10.1002\/pds.5374","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1330856","article-title":"Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache","volume":"44","author":"Bonfert M","year":"2013","unstructured":"Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics. 2013, 44:3-19. 10.1055\/s-0032-1330856","journal-title":"Neuropediatrics"},{"key":"ref43","article-title":"Pediatric migraine: recognition and treatment","volume":"105","author":"Hershey AD","year":"2005","unstructured":"Hershey AD, Winner PK. Pediatric migraine: recognition and treatment. J Am Osteopath Assoc. 2005, 105:2S-8S.","journal-title":"J Am Osteopath Assoc"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.677434","article-title":"Treating pediatric migraine: an expert opinion","volume":"13","author":"O'Brien HL","year":"2012","unstructured":"O'Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012, 13:959-66. 10.1517\/14656566.2012.677434","journal-title":"Expert Opin Pharmacother"},{"key":"ref45","article-title":"Antidepressants in migraine prophylaxis (Article in Japanese)","volume":"61","author":"Nagata E","year":"2009","unstructured":"Nagata E. Antidepressants in migraine prophylaxis (Article in Japanese). Brain Nerve. 2009, 61:1131-4.","journal-title":"Brain Nerve"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01800.x","article-title":"Amitriptyline in the prophylactic treatment of migraine and chronic daily headache","volume":"51","author":"Couch JR","year":"2011","unstructured":"Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011, 51:33-51. 10.1111\/j.1526-4610.2010.01800.x","journal-title":"Headache"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04052.x","article-title":"Prophylactic treatment of pediatric migraine","volume":"44","author":"Lewis DW","year":"2004","unstructured":"Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004, 44:230-7. 10.1111\/j.1526-4610.2004.04052.x","journal-title":"Headache"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00085.x","article-title":"Effectiveness of amitriptyline in the prophylactic management of childhood headaches","volume":"40","author":"Hershey AD","year":"2000","unstructured":"Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000, 40:539-49. 10.1046\/j.1526-4610.2000.00085.x","journal-title":"Headache"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12081","article-title":"Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial","volume":"128","author":"Kalita J","year":"2013","unstructured":"Kalita J, Bhoi SK, Misra UK. Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. Acta Neurol Scand. 2013, 128:65-72. 10.1111\/ane.12081","journal-title":"Acta Neurol Scand"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-008-0983-5","article-title":"Melatonin to prevent migraine or tension-type headache in children","volume":"29","author":"Miano S","year":"2008","unstructured":"Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008, 29:285-7. 10.1007\/s10072-008-0983-5","journal-title":"Neurol Sci"},{"key":"ref51","article-title":"Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine","volume":"22","author":"Israil A","year":"2013","unstructured":"Israil A, Ahmed S, Rahman KM, et al.. Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine. Mymensingh Med J. 2013, 22:93-100.","journal-title":"Mymensingh Med J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0219-x","article-title":"Melatonin for migraine prevention","volume":"15","author":"Peres MF","year":"2011","unstructured":"Peres MF. Melatonin for migraine prevention. Curr Pain Headache Rep. 2011, 15:334-5. 10.1007\/s11916-011-0219-x","journal-title":"Curr Pain Headache Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/892624","article-title":"Clinical uses of melatonin in pediatrics","volume":"2011","author":"S\u00e1nchez-Barcel\u00f3 EJ","year":"2011","unstructured":"S\u00e1nchez-Barcel\u00f3 EJ, Mediavilla MD, Reiter RJ. Clinical uses of melatonin in pediatrics. Int J Pediatr. 2011, 2011:892624. 10.1155\/2011\/892624","journal-title":"Int J Pediatr"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2005.077289","article-title":"Melatonin: prescribing practices and adverse events","volume":"90","author":"Waldron DL","year":"2005","unstructured":"Waldron DL, Bramble D, Gringras P. Melatonin: prescribing practices and adverse events. Arch Dis Child. 2005, 90:1206-7. 10.1136\/adc.2005.077289","journal-title":"Arch Dis Child"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/s1734-1140(11)70393-0","article-title":"Melatonin in experimental seizures and epilepsy","volume":"63","author":"Banach M","year":"2011","unstructured":"Banach M, Gurdziel E, J\u0119drych M, Borowicz KK. Melatonin in experimental seizures and epilepsy. Pharmacol Rep. 2011, 63:1-11. 10.1016\/s1734-1140(11)70393-0","journal-title":"Pharmacol Rep"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2007.00613.x","article-title":"Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects","volume":"16","author":"Lemoine P","year":"2007","unstructured":"Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007, 16:372-80. 10.1111\/j.1365-2869.2007.00613.x","journal-title":"J Sleep Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X233098","article-title":"Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes","volume":"23","author":"Wade AG","year":"2007","unstructured":"Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007, 23:2597-605. 10.1185\/030079907X233098","journal-title":"Curr Med Res Opin"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12663","article-title":"The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy","volume":"69","author":"Tseng PT","year":"2020","unstructured":"Tseng PT, Yang CP, Su KP, et al.. The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res. 2020, 69:e12663. 10.1111\/jpi.12663","journal-title":"J Pineal Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318254","article-title":"Migraine and risk of stroke","volume":"91","author":"\u00d8ie LR","year":"2020","unstructured":"\u00d8ie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. J Neurol Neurosurg Psychiatry. 2020, 91:593-604. 10.1136\/jnnp-2018-318254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:21:2:163","article-title":"Melatonin effect on rat body weight regulation in response to high-fat diet at middle age","volume":"21","author":"Puchalski SS","year":"2003","unstructured":"Puchalski SS, Green JN, Rasmussen DD. Melatonin effect on rat body weight regulation in response to high-fat diet at middle age. Endocrine. 2003, 21:163-7. 10.1385\/ENDO:21:2:163","journal-title":"Endocrine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299138-efficacy-of-melatonin-as-a-promising-intervention-for-migraine-prevention-a-systematic-review-of-randomized-control-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T16:15:02Z","timestamp":1730132102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299138-efficacy-of-melatonin-as-a-promising-intervention-for-migraine-prevention-a-systematic-review-of-randomized-control-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.72559","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,28]]}}}